L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis?

Int J Cardiol. 2007 Apr 4;116(3):300-8. doi: 10.1016/j.ijcard.2006.04.062. Epub 2006 Jul 24.

Abstract

L-Arginine is the substrate of endothelial nitric oxide synthase (eNOS) and the main precursor of nitric oxide (NO) in the vascular endothelium. L-Arginine improves endothelial function in patients with hypercholesterolemia, hypertension and smokers, while its role in diabetes remains unclear. Oral supplementation of L-arginine leads to a significant improvement of endothelium-dependent forearm vasodilation in hypercholesterolemic patients, while intravenous infusion of L-arginine improves endothelial function in healthy smokers. L-Arginine has anti-hypertensive properties, although its effects on endothelial function in hypertensive patients needs further evaluation. In conclusion, L-arginine administration may be useful in patients with premature atherosclerosis.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Arginine / pharmacology*
  • Arginine / physiology*
  • Arginine / therapeutic use
  • Atherosclerosis / drug therapy
  • Atherosclerosis / physiopathology*
  • Cardiovascular Agents / pharmacology*
  • Cardiovascular Agents / therapeutic use
  • Diabetes Mellitus / physiopathology
  • Endothelium, Vascular / metabolism
  • Female
  • Humans
  • Male
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Synthase Type III / metabolism
  • Time Factors
  • Vasodilation / drug effects
  • Vasodilation / physiology

Substances

  • Cardiovascular Agents
  • Nitric Oxide
  • Arginine
  • Nitric Oxide Synthase Type III